Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 1.00 |
| ▸ | MST1R | Q04912 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | TEK | Q02763 | 4/20 | 1.00 |
| ▸ | BTK | Q06187 | 4/20 | 1.00 |
| ▸ | HGF | P14210 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | FLT4 | P35916 | 3/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 0.77 |
| ▸ | LCK | P06239 | 3/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | AXL | P30530 | 3/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2868963 | 1.00 | MET (1.00) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL13511860 | 0.95 | MET (0.91) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2868521 | 0.95 | MET (0.91) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2863129 | 0.95 | MET (0.90) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2869076 | 0.95 | MET (1.00) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2861831 | 0.94 | MET (0.88) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2861036 | 0.89 | MET (0.80) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL3913569 | 0.88 | MET (0.79) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL15405418 | 0.88 | MET (0.79) | METMST1RKDRRPS6KB1TEK | |
| SCHEMBL2855807 | 0.88 | MET (1.00) | METMST1RKDRRPS6KB1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12454561-B2 | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer | MULTIVIR INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250172563-A1 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-05-29 | — | — | US | disclosed |
| US-20250163150-A1 | COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | I-MAB BIOPHARMA US LIMITED (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3768698-B1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240336622-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240042061-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY FOR THE INHIBITION OF PATHOGENS | MULTIVIR INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4274564-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-117042765-A | Azadirachtin analogs and methods of use thereof | 德克萨斯大学系统董事会 | 2023-11-10 | — | — | CN | disclosed |
| US-20230341408-A1 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023165615-A1 | COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | I-MAB BIOPHARMA CO., LTD. (CN) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| US-20220288225-A1 | MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES | NORTHWESTERN UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-20220226402-A1 | METHODS AND COMPOSITIONS COMPRISING ENHANCED TARGETED IMMUNE GENE THERAPY FOR THE TREATMENT OF CANCER | NORTHSHORE UNIVERSITY HEALTH SYSTEM (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2022140776-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY FOR THE INHIBITION OF PATHOGENS | MULTIVIR INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-4017876-A1 | MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES | Northwestern University (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021252519-A9 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163150-A1 | COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | KRAS, CD47, NRAS | MET 807/4885MST1R 61/4885KDR 2247/4885 |
| US-20240336622-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | MET 3899/4885MST1R 3224/4885KDR 1797/4885 |
| US-12384750-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MET 786/4885MST1R 2440/4885KDR 2344/4885 |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | TP53, HAVCR2, PDCD1LG2 | MET 154/4885MST1R 414/4885KDR 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.